本页面由Tiger Trade Technology Pte. Ltd.提供服务

Viking Therapeutics, Inc.

28.42
-0.0900-0.32%
成交量:131.51万
成交额:3,733.44万
市值:35.81亿
市盈率:-6.09
高:28.83
开:28.17
低:27.91
收:28.51
52周最高:43.15
52周最低:25.77
股本:1.26亿
流通股本:1.23亿
量比:0.37
换手率:1.07%
股息:- -
股息率:- -
每股收益(TTM):-4.6676
每股收益(LYR):-3.1920
净资产收益率:-88.85%
总资产收益率:-51.86%
市净率:8.77
市盈率(LYR):-8.90

数据加载中...

2025/01/06

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/11/15

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/11/08

关联方拟减持公告

Form 144 | VIKING THERAPEUTICS, INC. 董事 Lawson Macartney 拟减持2000股,总价约13.73万美元
2024/11/04

重要事件披露

Form 8-K - Current report
2024/10/28

关联方拟减持公告

Form 144 | Viking Therapeutics高管Greg Zante拟减持131687股,总价约1028万美元
2024/10/25

关联方拟减持公告

Form 144 | Viking Therapeutics董事 Rouan Sarah Kathryn 拟减持11000股,总价约88.94万美元
2024/10/25

关联方拟减持公告

Form 144 | Viking Therapeutics董事 Singleton拟减持16000股,总价约127万美元
2024/10/23

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/10/23

重要事件披露

Form 8-K - Current report
2024/10/18

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/09/20

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/09/20

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/21

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/21

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/14

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/07/30

关联方拟减持公告

Form144 | Viking Therapeutics高管Greg Zante拟减持16136股,总价约92.2万美元
2024/07/30

关联方拟减持公告

Form144 | Viking Therapeutics高管Brian Lian拟减持115,859股,总价约667万美元
2024/07/30

关联方拟减持公告

Form144 | Viking Therapeutics高管Marianna Mancini拟减持18026股,总价约102.99万美元